Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228681 · ClinicalTrials.gov registry record · Phase 2
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
A Phase 2 study of Advanced, Persistent, or Recurrent Endometrial Cancer, sponsored by GOG Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 20
- Study locations
NCT02228681: Completed Phase 2 study of Advanced, Persistent, or Recurrent Endometrial Cancer, sponsored by GOG Foundation.
NCT02228681 is a Phase 2 study of Advanced, Persistent, or Recurrent Endometrial Cancer that has completed, run by GOG Foundation. The registered enrollment target is 74 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02228681, a Phase 2 study of Advanced, Persistent, or Recurrent Endometrial Cancer, has completed, sponsored by GOG Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.
Primary Outcome
A confirmed complete or partial response as defined by RECIST 1.1 was considered a response. "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Letrozole
- DRUG Everolimus
- DRUG Medroxyprogesterone Acetate
Study Locations (20)
Georgia
- John B. Amos Cancer Center - Columbus
- Memorial Health University Medical Center - Savannah
Mississippi
- St. Dominic-Jackson Memorial Hospital - Jackson
- University of Mississippi Medical Center - Jackson
New Mexico
- New Mexico Cancer Alliance - Albuquerque
- Memorial Medical Center-Cancer Center - Albuquerque
New York
- Women's Cancer Care Associates - Albany
- SUNY Downstate Medical Center - Brooklyn
Ohio
- University Hospital Case Medical Center - Cleveland
- Ohio State University - Columbus
Colorado
- University of Colorado - Anschutz Cancer Pavilion - Aurora
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Maine
- Maine Medical Center - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-05-21 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 2 |
What the finished NCT02228681 record still lists
NCT02228681 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Advanced, Persistent, or Recurrent Endometrial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.
NCT02228681 names 20 study sites across 15 states, led by Georgia, Mississippi, New Mexico.
Frequently Asked Questions
What is clinical trial NCT02228681 about?
NCT02228681 is a clinical study titled "Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer". The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug co...
What is the current status of trial NCT02228681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2015-05-21. Estimated completion is 2024-08-22.
What conditions does trial NCT02228681 study?
This clinical trial studies the following conditions: Advanced, Persistent, or Recurrent Endometrial Cancer.
What interventions are being tested in trial NCT02228681?
The interventions under investigation include: Tamoxifen (DRUG), Letrozole (DRUG), Everolimus (DRUG), Medroxyprogesterone Acetate (DRUG).
Who is sponsoring clinical trial NCT02228681?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02228681 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Maine, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02228681's enrollment target sits among peer trials
74 920th of 2000 higher than 1,077 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI